Fingerprint Fingerprint is based on mining the text of the persons scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 2 Similar Profiles
Pharmacokinetics Medicine & Life Sciences
Verapamil Medicine & Life Sciences
Antipyrine Medicine & Life Sciences
Half-Life Medicine & Life Sciences
Obesity Medicine & Life Sciences
Benzodiazepines Medicine & Life Sciences
Diazepam Medicine & Life Sciences
Acetaminophen Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1972 2017

Improving the tools of clinical pharmacology: Goals for 2017 and beyond

Zineh, I., Abernethy, D., Hop, C. E. C. A., Bello, A., McClellan, M. B., Daniel, G. W. & Romine, M. H. Jan 1 2017 In : Clinical Pharmacology and Therapeutics. 101, 1, p. 22-24 3 p.

Research output: Contribution to journalArticle

Drug Evaluation
Clinical Pharmacology
Delivery of Health Care

GPS for QSP: A summary of the ACoP6 symposium on quantitative systems pharmacology and a stage for near-term efforts in the field

Musante, C. J., Abernethy, D. R., Allerheiligen, S. R., Lauffenburger, D. A. & Zager, M. G. Sep 1 2016 In : CPT: Pharmacometrics and Systems Pharmacology. 5, 9, p. 449-451 3 p.

Research output: Contribution to journalReview article

Pharmacology
Systems Biology
Drug Discovery
Molecular Biology

In Memoriam: David A Flockhart, 1952-2015

Greenblatt, D. J. & Abernethy, D. R. 2016 In : Clinical Pharmacology in Drug Development.

Research output: Contribution to journalArticle

Linking MedDRA®-Coded Clinical Phenotypes to Biological Mechanisms by the Ontology of Adverse Events: A Pilot Study on Tyrosine Kinase Inhibitors

Sarntivijai, S., Zhang, S., Jagannathan, D. G., Zaman, S., Burkhart, K. K., Omenn, G. S., He, Y., Athey, B. D. & Abernethy, D. R. Mar 22 2016 In : Drug Safety. p. 1-11 11 p.

Research output: Contribution to journalArticle

Biological Ontologies
Protein-Tyrosine Kinases
Phenotype
Monoclonal Antibodies
United States Food and Drug Administration

Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5

Yoshida, K., Sun, B., Zhang, L., Zhao, P., Abernethy, D., Nolin, T., Rostami-Hodjegan, A., Zineh, I. & Huang, S. M. 2016 In : Clinical Pharmacology and Therapeutics.

Research output: Contribution to journalArticle

Cytochrome P-450 CYP3A
Cytochrome P-450 CYP2D6
Chronic Renal Insufficiency
Pharmacokinetics
Drug Evaluation